Immutep has initiated a Phase I clinical trial of its lead product ImmuFact IMP321 in metastatic renal cell carcinoma. This is the company's first clinical trial targeting cancer. ImmuFact IMP321 is a potent natural human T-cell immunostimulatory factor designed to amplify the T-cell immune response through activation of dendritic cells and more efficient antigen presentation to T-cells.
The single-center, open-label study is designed to assess the safety and tolerability of six subcutaneous injections of IMP321 at two-week intervals. Additional patients may be recruited into the trial to provide more data on safety or response rates.